Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers. Transcript So, I wanted to talk to you today about pleural effusions. Pleural effusions — it’s a complex term, and it’s a very common problem, so
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 15
Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE). Transcript With the pleural fluid that’s built up around the lung — this fluid that exist in between the linings, or as we discussed
A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works. Transcript So we’re talking today about pleural fluid — fluid that resides around the lung, in-between this space that we’re
Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE). Transcript So we’re talking today about pleural fluid, the fluid that builds up around the lung — fluid that causes people be short of breath, often have symptoms like cough
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chiefof Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University